Rationaler for behandling med januskinase 1/2-hæmning af svært syge patienter med COVID-19-pneumoni
Research output: Contribution to journal › Review › Research › peer-review
Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.
Translated title of the contribution | Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia |
---|---|
Original language | Danish |
Article number | V04200234 |
Journal | Ugeskrift for Laeger |
Volume | 182 |
Issue number | 25 |
Number of pages | 9 |
ISSN | 0041-5782 |
Publication status | Published - 2020 |
Links
- https://ugeskriftet.dk/files/scientific_article_files/2020-06/v04200234_web.pdf
Final published version
ID: 269690725